KBC Group NV Sells 136,701 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• KBC Group NV cut its IDEXX Laboratories stake by 44.2% in the first quarter, selling 136,701 shares and leaving it with 172,679 shares valued at about $97.0 million.
• Despite the sale, institutional ownership remains high, with hedge funds and other institutions holding about 87.84% of IDEXX’s shares. Several other investors also made modest additions to their positions.
• Analysts remain broadly positive but have trimmed targets: IDEXX has a Moderate Buy consensus, with six Buy ratings and four Hold ratings, while the average price target stands at $751.

KBC Group NV trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 44.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 172,679 shares of the company's stock after selling 136,701 shares during the period. KBC Group NV owned about 0.22% of IDEXX Laboratories worth $97,027,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Harbour Investments Inc. grew its position in shares of IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company's stock worth $92,000 after purchasing an additional 16 shares in the last quarter. CWA Asset Management Group LLC lifted its holdings in IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company's stock worth $344,000 after purchasing an additional 17 shares in the last quarter. Rockland Trust Co. lifted its holdings in IDEXX Laboratories by 4.4% in the 4th quarter. Rockland Trust Co. now owns 425 shares of the company's stock worth $288,000 after purchasing an additional 18 shares in the last quarter. Prime Capital Investment Advisors LLC boosted its stake in IDEXX Laboratories by 0.5% in the 4th quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company's stock worth $2,654,000 after purchasing an additional 18 shares during the period. Finally, Pinnacle Associates Ltd. boosted its stake in IDEXX Laboratories by 1.5% in the 4th quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company's stock worth $830,000 after purchasing an additional 18 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on IDXX. Weiss Ratings lowered shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a report on Tuesday, July 14th. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating for the company in a research report on Tuesday, April 28th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a "neutral" rating and a $650.00 target price for the company. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating for the company in a research note on Tuesday, March 31st. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $751.00.

IDEXX Laboratories Stock Performance

IDXX opened at $567.44 on Monday. The stock has a 50-day moving average of $554.49 and a 200 day moving average of $599.33. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $513.02 and a 12 month high of $769.98. The firm has a market cap of $44.76 billion, a P/E ratio of 41.78, a P/E/G ratio of 3.10 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company's quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.